Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients
Conditions: ALK-positive Non-small Cell Lung Cancer; Real World Study Interventions: Drug: Lorlatinib Sponsors: Sichuan Cancer Hospital and Research Institute Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Hospitals | Lung Cancer | Non-Small Cell Lung Cancer | Research | Study